Virus-like particle-based vaccines targeting the <i>Anopheles</i> mosquito salivary protein TRIO

Malaria is a highly lethal infectious disease caused by <i>Plasmodium</i> parasites. These parasites are transmitted to vertebrate hosts when mosquitoes of the <i>Anopheles</i> genus probe for a blood meal. Sporozoites, the infectious stage of <i>Plasmodium</i>, transit to the liver within hours of injection into the dermis. Vaccine efforts are hindered by the complexity of the parasite's lifecycle and the speed at which the infection is established in the liver. In an effort to enhance immunity against <i>Plasmodium</i>, we produced a virus-like particle (VLP)-based vaccine displaying an epitope of TRIO, an <i>Anopheles</i> salivary protein that has been shown to enhance mobility and dispersal of sporozoites in the dermis. Previous work demonstrated that passive immunization with TRIO offered protection from liver infection and acted synergistically with a <i>Plasmodium</i>-targeted vaccine. Immunization of mice with TRIO VLPs resulted in high-titer and long-lasting antibody responses that did not significantly drop for over 18 months post-immunization. TRIO VLPs were similarly immunogenic when combined with an anti-malaria vaccine targeting the L9 epitope of the <i>Plasmodium falciparum</i> circumsporozoite protein. However, when used in a malaria challenge mouse model, TRIO VLPs only provided modest protection from infection and did not boost the protection provided by L9 VLPs.IMPORTANCEProteins present in the salivary glands of mosquitos have been shown to enhance the transmission efficiency of mosquito-borne pathogens, suggesting that interventions targeting the activity of these proteins could reduce transmission. Here, we looked at the efficacy of a vaccine targeting TRIO, an <i>Anopheles</i> mosquito salivary protein that has been reported to enhance <i>Plasmodium falciparum</i> malaria infection. We show that this vaccine can elicit strong anti-TRIO antibody responses, but these antibodies only result in a modest decrease in infection.

Authors

Institutions

Publication Details

Journal
mSphere
Published
2025-01-29
DOI
https://doi.org/10.1128/msphere.00798-24
Citations
6
Primary Topic
Malaria Research and Control
Type
article
Field-Weighted Citation Impact
11.27

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Virus-like particle-based vaccines targeting the Anopheles mosquito salivary protein TRIO

Fidel Zavala, Alexandra Francian, Bryce Chackerian, Yevel Flores-García et al.
6 citations
mSphere
Malaria Research and Control
11.27
article

Virus-like particle-based vaccines targeting the Anopheles mosquito salivary protein TRIO

Fidel Zavala, Alexandra Francian, Bryce Chackerian, Yevel Flores-García, Nikolai Petrovsky, John R. Powell
article en
6 citations

Abstract

Malaria is a highly lethal infectious disease caused by <i>Plasmodium</i> parasites. These parasites are transmitted to vertebrate hosts when mosquitoes of the <i>Anopheles</i> genus probe for a blood meal. Sporozoites, the infectious stage of <i>Plasmodium</i>, transit to the liver within hours of injection into the dermis. Vaccine efforts are hindered by the complexity of the parasite's lifecycle and the speed at which the infection is established in the liver. In an effort to enhance immunity against <i>Plasmodium</i>, we produced a virus-like particle (VLP)-based vaccine displaying an epitope of TRIO, an <i>Anopheles</i> salivary protein that has been shown to enhance mobility and dispersal of sporozoites in the dermis. Previous work demonstrated that passive immunization with TRIO offered protection from liver infection and acted synergistically with a <i>Plasmodium</i>-targeted vaccine. Immunization of mice with TRIO VLPs resulted in high-titer and long-lasting antibody responses that did not significantly drop for over 18 months post-immunization. TRIO VLPs were similarly immunogenic when combined with an anti-malaria vaccine targeting the L9 epitope of the <i>Plasmodium falciparum</i> circumsporozoite protein. However, when used in a malaria challenge mouse model, TRIO VLPs only provided modest protection from infection and did not boost the protection provided by L9 VLPs.IMPORTANCEProteins present in the salivary glands of mosquitos have been shown to enhance the transmission efficiency of mosquito-borne pathogens, suggesting that interventions targeting the activity of these proteins could reduce transmission. Here, we looked at the efficacy of a vaccine targeting TRIO, an <i>Anopheles</i> mosquito salivary protein that has been reported to enhance <i>Plasmodium falciparum</i> malaria infection. We show that this vaccine can elicit strong anti-TRIO antibody responses, but these antibodies only result in a modest decrease in infection.

mSphereVol. 10(2)
Johns Hopkins University (US), University of New Mexico (US), Vaxine (Australia) (AU)
National Institutes of Health, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases
Good health and well-being
Openalex Percentile: Top 2%
Malaria Research and Control
11.27
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.